1. Acknowledgement to Referees

   Acknowledgement to Referees 07 November 2022 Pages: 1243 - 1247

2. Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease

   • Jaimin Patel
   • Nikhil Panicker
   • Ted M. Dawson

   Leading Article 15 November 2022 Pages: 1249 - 1267

   

3. Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis

   • Angelo Antonini
   • Rajesh Pahwa
   • K. Ray Chaudhuri

   Systematic Review Open access 21 November 2022 Pages: 1269 - 1283

   

4. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis

   • Léorah Freeman
   • Erin E. Longbrake
   • Timothy Vollmer

   Review Article Open access 09 November 2022 Pages: 1285 - 1299

   

5. A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients

   • Hui Yang
   • YuJun Zhang
   • WenSheng Zhang

   Original Research Article 16 November 2022 Pages: 1301 - 1311

   

6. Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis

   • Bonaventure Y. Ip
   • Ho Ko
   • Thomas W. Leung

   Original Research Article Open access 24 November 2022 Pages: 1313 - 1324

   

7. Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects

   • Juri-Alexander Witt
   • Guido Widman
   • Christoph Helmstaedter

   Original Research Article Open access 02 November 2022 Pages: 1325 - 1330

   

8. Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder”

   • Alok Singh
   • Mahesh Kumar Balasundaram

   Letter to the Editor 04 November 2022 Pages: 1331 - 1332

9. Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”

   • Azmi Nasser
   • Joseph T. Hull
   • Ann Childress

   Letter to the Editor Open access 04 November 2022 Pages: 1333 - 1335